RNA epigenetic modifications have uncovered as not only an intermediary structure between DNA and protein or an effector ...

Nissan Chemical Corporation and Sanwa Kagaku Kenkyusho Co. Ltd. (SKK) have entered an agreement to codevelop SK-2407/SN-001 for the treatment of dentatorubral-pallidoluysian atrophy (DRPLA) in Japan.

BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

H.C. Wainwright initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $45 price target Ionis is a commercial-stage biotech ...

In a growing global trend, bacteria are evolving new ways to maneuver around medical treatments for a variety of infections.

The U.S. Food and Drug Administration approved treatment for 11 patients with the rare familial ALS caused by mutations in ...

RNA therapeutics market is expanding, driven by advancements in gene therapy, personalized medicine, and RNA-based drug delivery, along with rising research in mRNA vaccines, antisense ...

Budget cuts, delays to grant reviews, and layoffs of federal workers at agencies like the NIH and the National Science Foundation have affected nearly every research organization in the US. If ...

Discover how RNA therapeutics are reshaping medicine, offering new treatments for previously undruggable targets.

For transcription, a solution containing 2 μM of the double-stranded DNA, 6.25 mM rNTP, 80 mM HEPES-KOH pH 7.5, 24 mM MgCl 2, 2 mM spermidine, 40 mM DTT, 20 μg/mL pyrophosphatase (Roche) and a ...

The discovery could pave the way for a groundbreaking RNA-based multi-cancer treatment. Alternative RNA splicing functions like a film editor rearranging scenes from the same footage to create ...

March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide .